JORGE ANTONIO HERNANDEZ MIRAMONTES,JORGE ALBERTO HERNANDEZ VILLANUEVA
申请号：
MX2015003641
公开号：
MX2015003641A
申请日:
2015.03.20
申请国别(地区):
MX
年份:
2016
代理人:
摘要：
Currently, the treatment for patients with end-stage renal disease (stage V) consists in renal replacement therapy (hemodialysis, peritoneal dialysis or renal transplant), which is outstandingly expensive, thereby entailing a poor quality of life. The present invention discloses a mixture of carboxylic acids, citric acid, succinic acid, fumaric acid and malic acid, and any of the possible combinations thereof. Said product is preferably orally or intravenously administered in the therapy of patients with chronic renal failure, hyperamonemia or human conditions associated with a negative nitrogen balance. The product of the present invention is further beneficial for lowering the serum values of urea and serum ammonium, while by transamination of the oxalacelate formed via succinate and malate and fumarate, it promotes the biosynthesis of non- essential amino acids. Also, by transamination of the alpha-ketoglutarate formed via citrate, it generates glutamic acid and amino acids related therewith such as glutamine. This treatment is useful for preventing, preserving and improving renal function. In other patients it causes deterioration of renal function to be delayed, and the imperious need of a renal replacement therapy. In other patients, it is useful as a treatment complementary to the renal replacement therapy for improving the patient’s quality of life and the laboratory parameters.Actualmente el tratamiento para pacientes con enfermedad renal terminal (estadio V) consiste en terapia renal sustitutiva (hemodiálisis, diálisis peritoneal o transplante renal)； extraordinariamente costosa que conlleva una pobre calidad de vida. Nuestro invento es una mezcla de ácidos carboxílicos: ácido cítrico, ácido succínico, ácido fumárico y ácido málico, y cualesquiera de sus combinaciones posibles. Dicho producto se utiliza preferentemente vía oral o también vía intravenosa, en el tratamiento de pacientes con insuficiencia renal crónica, hiperamonemia o condiciones humanas que
